Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Operating Expenses of $14.9 million for Q1 2026, up 88.73% year-over-year from $7.9 million in Q1 2025, and up 31.41% quarter-over-quarter from $11.3 million in Q4 2025.
Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Operating Expenses for 14 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 88.73% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $45.6 million (up 125.6% YoY), while the FY2025 annual figure was $38.6 million, up 173.87% from the prior year.
- Operating Expenses improved to $14.9 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $31.3 million in Q3 2023 and bottomed at -$54.9 million in Q4 2023.
- Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $11.3 million in 2025.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 416.14% — and 2025, when it surged 347.47%.
- Palvella Therapeutics' Operating Expenses stood at $17.4 million in 2022, then sank by 416.14% to -$54.9 million in 2023, then jumped by 107.95% to $4.4 million in 2024, then jumped by 158.91% to $11.3 million in 2025, then soared by 31.41% to $14.9 million in 2026.
- Business Quant data shows PVLA's Operating Expenses at $14.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 21.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.41 Mn |
| Mar 31, 2026 | 14.86 Mn |
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 10.18 Mn |
| Jun 30, 2025 | 9.25 Mn |
| Mar 31, 2025 | 7.87 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | 5.06 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | -54.90 Mn |
| Sep 30, 2023 | 31.33 Mn |
| Jun 30, 2023 | 17.99 Mn |
| Mar 31, 2023 | 17.45 Mn |
| Dec 31, 2022 | 17.37 Mn |
| Sep 30, 2022 | 17.54 Mn |
| Jun 30, 2022 | 16.03 Mn |
| Mar 31, 2022 | 18.45 Mn |
| Dec 31, 2021 | 19.44 Mn |
| Sep 30, 2021 | 23.07 Mn |